Freestone Capital Holdings LLC lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 6.3% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 36,940 shares of the company's stock after purchasing an additional 2,185 shares during the quarter. Freestone Capital Holdings LLC's holdings in Zoetis were worth $6,082,000 as of its most recent filing with the SEC.
A number of other large investors have also recently made changes to their positions in ZTS. Navigoe LLC purchased a new stake in shares of Zoetis during the fourth quarter worth approximately $30,000. Cornerstone Planning Group LLC increased its stake in shares of Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after buying an additional 88 shares during the period. Migdal Insurance & Financial Holdings Ltd. increased its stake in shares of Zoetis by 87.6% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock worth $42,000 after buying an additional 120 shares during the period. Sound Income Strategies LLC increased its stake in shares of Zoetis by 141.4% during the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock worth $46,000 after buying an additional 164 shares during the period. Finally, Bfsg LLC increased its stake in shares of Zoetis by 614.6% during the first quarter. Bfsg LLC now owns 293 shares of the company's stock worth $48,000 after buying an additional 252 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling at Zoetis
In related news, EVP Roxanne Lagano sold 652 shares of the stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the sale, the executive vice president directly owned 15,129 shares of the company's stock, valued at $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.18% of the stock is currently owned by corporate insiders.
Zoetis Price Performance
ZTS stock opened at $154.15 on Friday. The company has a market capitalization of $68.32 billion, a P/E ratio of 26.53, a PEG ratio of 2.47 and a beta of 0.88. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The business has a 50 day simple moving average of $154.94 and a 200-day simple moving average of $159.13. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05.
Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%. The company's revenue was up 4.2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.56 earnings per share. As a group, equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.
Zoetis Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 annualized dividend and a dividend yield of 1.3%. Zoetis's dividend payout ratio (DPR) is currently 34.42%.
Analyst Ratings Changes
ZTS has been the topic of a number of recent research reports. UBS Group cut their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Leerink Partnrs lowered shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Piper Sandler restated an "overweight" rating and set a $215.00 target price (up from $210.00) on shares of Zoetis in a research note on Monday, August 11th. Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and dropped their price target for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and dropped their price target for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Zoetis currently has a consensus rating of "Moderate Buy" and a consensus target price of $202.43.
View Our Latest Analysis on ZTS
Zoetis Profile
(
Free Report)
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
See Also
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.